Rybelsus (Oral Semaglutide): Uses, Dosing, and Results

What is Rybelsus approved for?

Rybelsus is semaglutide in tablet form, approved by FDA on 20 September 2019 [3]. Its label, effective 30 January 2026, lists two indications for adults with type 2 diabetes: as an adjunct to diet and exercise to improve glycemic control, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes at high risk for these events [1].

Weight loss is not one of them. Rybelsus has no obesity indication. The oral semaglutide that is approved for weight management is a different product: Wegovy 25 mg tablets, approved on 22 December 2025 for adults [4].

Rybelsus is also no longer the only oral semaglutide for diabetes. Ozempic tablets (1.5 mg, 4 mg and 9 mg) sit under the same FDA approval [3], and the label states that Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis [1].

How do you take Rybelsus?

Rybelsus is taken once daily in the morning on an empty stomach with up to 4 ounces of plain water. The tablet is swallowed whole, and food, beverages and other oral medicines are delayed for at least 30 minutes. If a dose is missed, it is skipped and the next dose is taken the following day; no more than one tablet is taken per day [1].

Each tablet pairs semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), an absorption enhancer that helps the peptide cross the stomach lining [5].

The dose steps up on a fixed schedule [1]:

• Days 1 to 30: 3 mg once daily. The label states this dose is not effective for glycemic control.
• Days 31 to 60: 7 mg once daily.
• Day 61 onward: 7 mg or 14 mg once daily.

Rybelsus comes in 3 mg, 7 mg and 14 mg tablets [3].

What results should you expect?

The clearest efficacy data come from PIONEER 1, a 26-week trial of 703 adults with type 2 diabetes not controlled by diet and exercise alone. Participants were randomly assigned to 3 mg, 7 mg, 14 mg or placebo [2].

Against placebo, HbA1c fell by 0.6, 0.9 and 1.1 percentage points with 3, 7 and 14 mg on the treatment-policy analysis, which counts people who stopped the drug. On the trial-product analysis (on treatment, no rescue medication) the drops were 0.7, 1.2 and 1.4 points. Placebo-adjusted body weight differences were minus 0.1, 0.9 and 2.3 kg on the treatment-policy analysis, and minus 0.2, 1.0 and 2.6 kg on the trial-product analysis [2].

Treatment was discontinued in 2.3% to 7.4% of the oral semaglutide groups versus 2.2% on placebo [2].

Does Rybelsus lower cardiovascular risk?

Yes. The label carries a cardiovascular risk-reduction indication, added with the October 2025 update [1]. The supporting trial was SOUL: 9,650 adults aged 50 or older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, randomly assigned to oral semaglutide up to 14 mg daily or placebo. Over a median follow-up of 49.5 months, major adverse cardiovascular events occurred in 12.0% on oral semaglutide versus 13.8% on placebo (hazard ratio 0.86, 95% CI 0.77 to 0.96) [6].

An earlier trial, PIONEER 6, was built to rule out excess cardiovascular risk rather than to show benefit. In 3,183 adults with type 2 diabetes at high cardiovascular risk, over a median 15.9 months, major adverse cardiovascular events occurred in 3.8% on oral semaglutide and 4.8% on placebo (HR 0.79, 0.57 to 1.11) [7].

The large SELECT result belongs to a different product and population: injectable semaglutide 2.4 mg in 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes, where the same three-part endpoint occurred in 6.5% versus 8.0% (HR 0.80) over mean follow-up of 39.8 months [8].

What are the side effects?

Gastrointestinal effects dominate, and they scale with dose. In the label's placebo-controlled pool (placebo, 7 mg, 14 mg) the rates were: nausea 6%, 11% and 20%; abdominal pain 4%, 10% and 11%; diarrhea 4%, 9% and 10%; decreased appetite 1%, 6% and 9%; vomiting 3%, 6% and 8%; constipation 2%, 6% and 5% [1].

Any gastrointestinal reaction occurred in 21%, 32% and 41%; severe gastrointestinal reactions in 0.3%, 0.6% and 2.0%; and gastrointestinal reactions led to discontinuation in 1%, 4% and 8% [1]. The label states that most nausea, vomiting and diarrhea occurred during dose escalation [1].

Semaglutide tablets carry warnings for acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia with insulin or sulfonylureas, serious hypersensitivity reactions, diabetic retinopathy complications, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation [1].

On retinopathy, a pooled analysis of glycemic control trials reported diabetic retinopathy-related adverse reactions in 4.2% of patients on semaglutide tablets versus 3.8% on comparator, and the label says patients with a history of diabetic retinopathy should be monitored [1].

On low blood sugar, a 52-week trial adding oral semaglutide to insulin found glucose below 54 mg/dL in 32% on placebo, 26% on 7 mg and 30% on 14 mg, and the label advises considering a lower dose of insulin or a sulfonylurea when starting [1].

Rybelsus carries a boxed warning for thyroid C-cell tumors seen in rodents, with human relevance unknown, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. The US label does not mention NAION (a form of sudden vision loss); the European regulator concluded in June 2025 that it is a very rare side effect, up to 1 in 10,000 people, of semaglutide medicines including Rybelsus [9].

The Rybelsus label recommends stopping semaglutide tablets at least 2 months before a planned pregnancy because of the long washout period. In the lactation study, semaglutide was below the quantification limit in human milk, while SNAC and/or its metabolites were present; breastfeeding is not recommended during treatment [1].

How does Rybelsus compare with other GLP-1 drugs?

Wegovy 2.4 mg injection is the weight-management semaglutide. In STEP 1, 1,961 adults with obesity or overweight and no diabetes lost 14.9% of body weight on semaglutide versus 2.4% on placebo over 68 weeks [10]. At 14 mg, Rybelsus produced weight differences of roughly 2.3 to 2.6 kg against placebo over 26 weeks in PIONEER 1 [2].

Oral semaglutide at 25 mg has since been tested for weight management and approved as Wegovy tablets. In a 71-week trial of 307 adults with obesity and no diabetes, oral semaglutide 25 mg produced 13.6% weight loss versus 2.2% on placebo at the week-64 primary endpoint [11].

Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is a dual GIP and GLP-1 receptor agonist rather than a pure GLP-1 drug. In the open-label SURPASS-2 trial of 1,879 adults with type 2 diabetes, 40 weeks of tirzepatide 15 mg lowered HbA1c 2.30 points versus 1.86 with injectable semaglutide 1 mg, and weight reduction was 5.5 kg greater with tirzepatide 15 mg [12]. That comparison used injectable semaglutide, not Rybelsus.

Who is Rybelsus for?

Rybelsus is labeled for adults with type 2 diabetes: for glycemic control and, in those at high cardiovascular risk, for cardiovascular risk reduction [1]. It is dosed in the morning on an empty stomach with a 30-minute wait before food, drink or other oral medicines [1]. It has no weight-management indication, and the weight differences reported in its own trial were small [2].